Capacitive hyperthermia as an alternative to brachytherapy in DNA damages of human prostate cancer cell line (DU-145)
/in Hyperthermia, International Publications, Prostate Cancer /von 2018-10-25 / Int. J. Radiat. Biol. 2019 Feb;95(2):193-200Empowering dendritic cell cancer vaccination: the role of combinatorial strategies
/in Dendritic Cells, International Publications /von 2018-10-22 / Cytotherapy 2018 Nov;20(11):1309-1323Nobelpreis für Medizin 2018 für die Entwicklung neuer Krebstherapien mit Checkpoint Inhibitoren
/0 Kommentare/in Externe Meldungen, IOZK Meldungen /von rootImmune Function and Micronutrient Requirements Change over the Life Course
/in International Publications, Micronutrients /von 2018-10-17 / 2018 Oct;10(10)Long-term survival of pancreatic cancer patients treated with multimodal therapy combined with WT1-targeted dendritic cell vaccines
/in Dendritic Cells, International Publications, Pancreatic Cancer /von 2018-10-12 / Hum Vaccin Immunother 2019;15(2):397-406Dendritic cell vaccine with Ag85A enhances anti-colorectal carcinoma immunity
/in Colorectal Cancer, Dendritic Cells, International Publications /von 2018-10-11 / Exp Ther Med 2018 Dec;16(6):5123-5129Phase I/II clinical trial of a Wilms‘ tumor 1-targeted dendritic cell vaccination-based immunotherapy in patients with advanced cancer
/in Dendritic Cells, International Publications /von 2018-10-10 / Cancer Immunol. Immunother. 2019 Jan;68(1):121-130Vitamin C and immune cell function in inflammation and cancer
/in International Publications, Micronutrients /von 2018-10-08 / 2018 10;46(5):1147-1159Combining Tumor Vaccination and Oncolytic Viral Approaches with Checkpoint Inhibitors: Rationale, Pre-Clinical Experience, and Current Clinical Trials in Malignant Melanoma
/in Checkpoint-Inhibitors, Dendritic Cells, International Publications, Malignant Melanoma, Newcastle Disease Virus /von 2018-10-01 / Am J Clin Dermatol 2018 Oct;19(5):657-670
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution